Latest News | Biocon Gets 4 Observations from USFDA for Andhra Facility

New Delhi, Jun 22 (PTI) Biotechnology player Biocon on Saturday said the US health regulator has issued four observations after inspecting its manufacturing plant in Andhra Pradesh.

The US Food and Drug Administration (USFDA) concluded a GMP inspection of the company's API facility (Site 5), located at Visakhapatnam, Andhra Pradesh, on June 21, 2024, the company said in a regulatory filing.

Also Read | Who Is Nyay Bindu? All About Rouse Avenue Court Judge Who Granted Bail to Arvind Kejriwal in Money Laundering Case Linked to Delhi Liquor Policy.

"Four observations were cited at the end of the inspection, which we will be addressing within the stipulated time," it added.

As per the USFDA, a Form 483 (with observations) is issued to a firm's management at the conclusion of an inspection, when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act.

Also Read | Punjab State Dear Summer Special Bumper Lottery 2024 Draw Results To Be Declared on June 29 at punjabstatelotteries.gov.in, Know Prize Money and How To Check Winning Numbers Online.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)